NCT01648530已完成不适用
Chronic Migraine Epidemiology and Outcomes Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 16,789
- 主要终点
- Migraine Disability Assessment (MIDAS)
研究概览
简要总结
This is a population internet-based study to characterize migraine clinical course and impact on family.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of migraine
- •U.S. Member of Survey Panel
- •Household member of study participant
- •Ability to complete internet-based questionnaires
排除标准
- •No access to internet
结局指标
主要结局
Migraine Disability Assessment (MIDAS)
时间窗: 12 Months
The Midas score is a patient completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability. The Midas scores assessed at Months 3, 6, 9 and 12 were averaged.
Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM)
时间窗: Baseline
EM is defined as \<15 headache days/month and CM is defined as ≥15 headache days/month.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult ParticipantsMigraineNCT05653986AbbVie391
已完成
2 期
Efficacy of OnabotulinumtoxinA in MigraineMigraineNCT04578782IRCCS National Neurological Institute "C. Mondino" Foundation32
已完成
不适用
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®Migraine DisordersNCT02502123Allergan215
招募中
不适用
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic MigraineChronic MigraineEpisodic MigraineMigraineNCT06603558AbbVie3,000
Unknown
3 期
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)MigraineNCT05127954AbbVie1,200